版本:
中国

BRIEF-Crispr and Casebia announce commercial license agreement with Maxcyte

March 14 Crispr Therapeutics Ag

* Crispr Therapeutics and Casebia Therapeutics announce commercial license agreement with Maxcyte

* Maxcyte will supply systems Co and Casebia as part of license agreement and will receive upfront, milestone, and sales-based payments

* Says commercial license builds on an existing research and clinical licensing agreement for select disease areas

* Crispr, Casebia will obtain non-exclusive commercial-use rights to Maxcyte's cell engineering platform to develop crispr/CAS9-based therapies for SCID Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐